Justin Kim

Justin Kim serves as an Associate Professor at Georgia Institute of Technology, leading a research program at the intersection of organic chemistry, chemical biology, and materials science with significant applications in drug discovery and biomaterials development.

His academic credentials include:

• Ph.D. in Organic Chemistry from Massachusetts Institute of Technology (2013)
• A.M. in Chemistry and A.B. in Chemistry and Physics from Harvard University (2007)

Prof. Kim's research employs a bottom-up molecular approach to address challenges in organic synthesis and biological systems. The Kim Lab specializes in bioorthogonal reaction development, chemoproteomics-based target discovery, and functionally adaptive biomaterials, with particular emphasis on lipid biochemistry and endocannabinoid systems. Their work bridges fundamental chemical reactivity with therapeutic applications, focusing on inflammation modulation, neurodegenerative disorders, and metabolic disease mechanisms.

Analysis of recent publications reveals a strong thematic focus on lipid mediators in disease pathology, particularly examining how viral infections (especially influenza) impact neurological conditions like multiple sclerosis through alterations in myelin lipidomes and oligodendrocyte function. A secondary research thread investigates postprandial glucose regulation using natural compounds and engineered biomaterials.

Major recognitions include:

• NSF CAREER Award (2023) for pioneering contributions to chemical biology
• Thieme Chemistry Journal Award (2021) for innovative synthetic methodologies
• NIH Director’s New Innovator Award (2018) supporting high-risk/high-reward research in endocannabinoid pharmacology

The Kim Lab operates with substantial grant support including the NIH New Innovator Award, enabling advanced instrumentation for lipidomics and molecular imaging. Current collaborations span immunology, neuroscience, and metabolic disease research, with emphasis on translating chemical tools into diagnostic and therapeutic platforms. While specific advisees aren't listed in source materials, the lab structure indicates mentorship of graduate researchers in chemical biology and organic synthesis.

The research group maintains active investigation of omega-3 endocannabinoids, bioorthogonal probes for target identification, and glucose-responsive biomaterials, with recent expansion into viral-neurological interactions and metabolic inflammation pathways.